Of note, molecular targeted therapy and immunotherapy may provide new options in addition to traditional surgery, radiotherapy, and chemotherapy; whether these new treatments affect NSCLC with BM requires further investigation although some recent studies show that epidermal growth factor receptor-targeted drugs can improve prognosis in lung cancer [31, 32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.